HRT is recommended as an effective treatment for managing oestrogen deficiency symptoms associated with the menopause

In 2015, the National Institute for Health and Care Excellence (NICE) published the NG23 guideline, titled Menopause: diagnosis and management, which makes the following recommendations for the use of HRT in the management of menopause:1

  • Adopt an individualised approach at all stages of diagnosis, investigation and management of menopause.
  • Offer women HRT for vasomotor symptoms after discussing with them the short-term (up to 5 years) and longer-term benefits and risks.
  • Consider HRT to alleviate low mood that arises as a result of the menopause.

In 2016, the International Menopause Society (IMS) published recommendations on women’s midlife health and HRT to help guide health-care professionals in optimising their management of women in the menopause transition and beyond.

The first three governing principles on HRT are the following:2

  • HRT remains the most effective therapy for vasomotor symptoms and urogenital atrophy
  • Other menopause-related complaints, such as joint and muscle pains, mood swings, sleep disturbances and sexual dysfunction (including reduced libido) may improve during HRT
  • Quality of life and sexual function may also improve

References

1. NICE. Menopause: diagnosis and management. Guideline NG23. 2015. Available from: www.nice.org.uk/guidance/ng23 [accessed March 2019].
2. Baber RJ et al.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19(2): 109-150.

Menu
Complete the survey